Mandate

Vinge advises Carnegie and Nordea in connection with the listing of Volati on Nasdaq Stockholm

November 17, 2016

Vinge advises Carnegie Investment Bank AB (publ) and Nordea Bank AB (publ) who are acting as Joint Global Coordinators and Joint Bookrunners in connection with the listing of the common shares and preference shares in Volati AB (publ) on Nasdaq Stockholm. The company has applied for the company’s shares to be admitted for trading and Nasdaq Stockholm has approved the company’s shares for listing subject to customary conditions. A prospectus is expected to be published on or around 18 November 2016 and first day of trading is expected to be on or around 30 November 2016.

Volati is an industrial group comprising 13 business units organised into three business areas: Trading, Industry and Consumer. Volati has some 40 operating companies in 15 countries, with Sweden accounting for the largest share of net sales. Acquisitions are central in Volati’s strategy and Volati primarily acquires companies with proven business models, leading market positions and strong cash flows at reasonable valuations, and develops these with an emphasis on long-term creation.   

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Sofie Bjärtun.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025